Company profile: Covis Pharma
1.1 - Company Overview
Company description
- Provider of branded and generic pharmaceutical products and injectables for life-threatening and serious medical conditions across cardiovascular, CNS, oncology, and acute care. Portfolio includes Alvesco for asthma, Omnaris and Zetonna for nasal allergies, Feraheme for iron deficiency anemia, and Duaklir and Tudorza Pressair for COPD.
Products and services
- Feraheme: Intravenous iron replacement produced for adult patients with iron deficiency anemia in chronic kidney disease or with unsatisfactory response to oral iron
- Duaklir Pressair: Combination inhaler constructed for treatment of chronic obstructive pulmonary disease, containing aclidinium bromide and formoterol in a single device
- Alvesco: Ciclesonide inhalation aerosol engineered for asthma treatment, available in 80 MCG/ACT and 160 MCG/ACT strengths
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Covis Pharma
ZymoGenetics
HQ: United States
Website
- Description: Provider of therapeutic protein discovery, development, and early manufacturing, supported by fully integrated research and development capabilities in scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, and clinical expertise; with an early focus on production systems for recombinant proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ZymoGenetics company profile →
SynDevRx
HQ: United States
Website
- Description: Provider of polymer-based drug conjugates for oncology, including evexomostat (SDX-7320), a polymer-drug conjugate that releases a fumagillol derivative in vivo to target cancer and systemic metabolic hormone dysfunction. Sponsors clinical trials across various cancer types, provides an expanded access program, and advances a pipeline focused on cancers sensitive to metabolic hormones, leveraging metabo-oncology and polymer-drug conjugation to improve safety and activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynDevRx company profile →
Antibe Therapeutics
HQ: Canada
Website
- Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antibe Therapeutics company profile →
Rosemont Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of oral liquid medicines for patients with swallowing difficulties, manufacturing and supplying 130+ formulations across therapeutic categories. Offers R&D for new low-excipient liquid medications, GMP and ICH Q10-compliant, regularly inspected manufacturing, international distribution to 27+ markets, and educational resources for healthcare professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rosemont Pharmaceuticals company profile →
Mavu Pharma
HQ: United States
Website
- Description: Provider of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mavu Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Covis Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Covis Pharma
2.2 - Growth funds investing in similar companies to Covis Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Covis Pharma
4.2 - Public trading comparable groups for Covis Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →